Best of ASCO 2024, Portland

Portland, OR US
June 22, 2024 to June 23, 2024

This CME-accredited oncology conference, Best of ASCO 2024, Portland, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2024 ASCO® Annual Meeting (ASCO2024) in June 2024. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2024 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

ORGANIZING COMMITTEE: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chair:

Julie Graff, MD - Oregon Health and Science University

VENUE INFORMATION

 A limited number of rooms have been booked at The Nines Portland at a discounted nightly rate of $209 per room for this conference's attendees and sponsors. Please book your room at the link here by Monday, May 27, 2024 to receive the discounted group rate.

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2024 and discuss their application in clinical settings

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 9.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 9.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.75 Contact Hours.
Course opens: 
12/06/2023
Course expires: 
08/31/2024
Event starts: 
06/22/2024 - 7:00am PDT
Event ends: 
06/23/2024 - 4:00pm PDT
Cost:
$350.00

DAY 1 - June 22nd, 2024


All times below are listed in Pacific Standard Time (PST).

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits

08:00 AM – 08:05 AM  Welcome


08:05 AM – 09:35 AM  Session 1 - Hematologic Malignancies

Session Chair: Stephen Spurgeon, MD

08:05 AM 08:35 AM  MDS/Leukemias - Vinod Pullarkat, MD

08:35 AM 09:05 AM  Multiple Myeloma - Amandeep Godara, MD, MBBS

09:05 AM 09:35 AM  Lymphoma & CLL - Stephen Spurgeon, MD


09:35 AM – 10:00 AM  Break & Exhibits


10:00 AM – 11:30 AM  Session 2 - Thoracic Oncology

Session Chair: Lucy Langer, MD

10:00 AM 10:30 AM  Early-Stage Lung Cancer - Rajat Thawani, MD, MBBS

10:30 AM 11:00 AM  Metastatic Lung Cancer - Chetan Vakkalagadda, MD

11:00 AM – 11:30 AM  Small Cell Lung Cancer - Rachel Sanborn, MD


11:30 AM – 12:45 PM  Session 3 - Case-based Presentations 1

Session Chair: Joseph Rosales, MD

11:30 AM 11:45 AM  Case 1: Sarcoma - Lara Davis, MD

11:45 AM 12:00 PM  Case 2: Brain Tumor Updates - Prakash Ambady, MD

12:00 PM 12:15 PM  Case 3: Head / Neck Cancer - Lauren Shih, MD

12:15 PM 12:30 PM  Case 4: Gynecologic Cancer - Joshua Z. Press, MD, MSc

12:30 PM 12:45 PM  Case 5: Palliative Care - Sarah Lowry, DNP, ACNP-BC, AOCNP, ACHPN


12:45 PM – 01:45 PM  Lunch & Exhibits

01:00 PM – 01:45 PM  Product Theater Sponsored by Exelixis in Studio Breakout Room 

Presentation Title: A Combination Treatment for Patients with Advanced Renal Cell Carcinoma

Speaker: John Sarantopoulos, MD | UT Health San Antonio-MD Anderson Cancer Center

* Non-CME Activity *


01:45 PM – 03:15 PM  Session 4 - Genitourinary Cancer

Session Chair: Julie Graff, MD

01:45 PM 02:15 PM  Prostate Cancer - Julie Graff, MD

02:15 PM 02:45 PM  Bladder Cancer - Ronald Ng, MD

02:45 PM 03:15 PM  Kidney Cancer - Scott Tykodi, MD, PhD


03:15 PM – 03:30 PM  Break & Exhibits


03:30 PM – 04:30 PM  Session 5 - Case-based Presentations 2

Session Chair: Fengting Yan, MD, PhD, FACP

03:30 PM  03:45 PM  Case 1: Geriatric Oncology - Gabrielle Meyers, MD

03:45 PM  04:00 PM  Case 2: GU Cancer - Julie Graff, MD

04:00 PM  04:15 PM  Case 3: GI Cancer - Selena Liu, MD

04:15 PM  04:30 PM  Case 4: Breast Cancer - Fengting Yan, MD, PhD, FACP


DAY 2 - June 23rd, 2024
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:15 AM  Addressing Global Cancer Health Disparities - Building a 200-Bed Cancer Hospital in Nepal - Justin Marquart


08:15 AM – 09:45 AM  Session 6 - GI Cancer

Session Chair: David Cosgrove, MD

08:15 AM 08:45 AM  Colorectal Cancer - Rachael Safyan, MD

08:45 AM 09:15 AM  Hepatobiliary and Pancreatic Malignancies - Adel Kardosh, MD, PhD

09:15 AM 09:45 AM  Upper GI Cancer - Emerson Chen, MD


09:45 AM – 10:15 AM  Break & Exhibits


10:15 AM – 11:45 AM  Session 7 - Breast Cancer

Session Chair: Sasha Stanton, MD, PhD

10:15 AM – 10:45 AM  Hormone Receptor Positive Breast Cancer - Sasha Stanton, MD, PhD

10:45 AM – 11:15 AM  Triple Negative Breast Cancer - Lynn Symonds, MD

11:15 AM 11:45 AM  HER2 Positive Breast Cancer - Sasha Stanton, MD, PhD 


11:45 AM  Adjourn

The Nines, Portland
525 SW Morrison St
Portland, OR 97204
United States

 A limited number of rooms have been booked at The Nines Portland at a discounted nightly rate of $209 per room for this conference's attendees and sponsors. Please book your room at the link here by Monday, May 27, 2024 to receive the discounted group rate.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Julie Graff, MD

has no relevant financial relationships to disclose at this time.
Session Chair(s)

David Cosgrove

has no relevant financial relationships to disclose at this time.

Lucy Langer, MD, MSHS

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Stephen Spurgeon, MD

has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Grant Or Contract) with Acerta;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Grant Or Contract) with Beigene;.
has a financial relationship (Grant Or Contract) with Profound Bio;.
has a financial relationship (Grant Or Contract) with BMS/Celgene;.
has a financial relationship (Grant Or Contract) with Schrodinger;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Merck;.

Sasha Stanton, MD PhD

has a financial relationship (Professional Services) with Margenza;.
has a financial relationship (Grant Or Contract) with IMV Inc;.
has a financial relationship (Professional Services) with Stanford Prebys Burnham;.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Emerson Chen, MD

has no relevant financial relationships to disclose at this time.

Lara Davis, MD

has a financial relationship (Independent contractor) with SpringWorks;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Inbrx;.
has a financial relationship (Independent contractor) with Daiichi Sankyo;.

Amandeep Godara, MD

has a financial relationship (Other) with Janssen;.

Julie Graff, MD

has no relevant financial relationships to disclose at this time.

Adel Kardosh, MD, PhD

has a financial relationship (Grant Or Contract) with Natera;.
has a financial relationship (Other) with exelixis;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Eisai;.
has a financial relationship (Other) with seagen;.

Ronald Ng, MD

has no relevant financial relationships to disclose at this time.

Vinod Pullarkat, MD, MRCP

has a financial relationship (Independent contractor) with sanofi;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with jazz;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with rigel;.
has a financial relationship (Independent contractor) with sobi;.
has a financial relationship (Independent contractor) with amgen;.

Rachael Safyan, MD

has a financial relationship (Other) with Mirati;.
has a financial relationship (Other) with Agenus;.
has a financial relationship (Grant Or Contract) with Verastem;.
has a financial relationship (Other) with Ipsen;.
has a financial relationship (Grant Or Contract) with Replimune;.
has a financial relationship (Other) with Guardant Health;.
has a financial relationship (Grant Or Contract) with Exelixis;.

Rachel Sanborn, M.D.

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with Mirati Therapeutics;.
has a financial relationship (Independent contractor) with Lilly Oncology;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Daiichi Sankyo;.
has a financial relationship (Independent contractor) with Sanofi Aventis;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Independent contractor) with EMD Serono;.
has a financial relationship (Independent contractor) with Macrogenics;.
has a financial relationship (Independent contractor) with GlaxoSmithKline;.

Stephen Spurgeon, MD

has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Grant Or Contract) with Beigene;.
has a financial relationship (Grant Or Contract) with Profound Bio;.
has a financial relationship (Grant Or Contract) with BMS/Celgene;.
has a financial relationship (Grant Or Contract) with Schrodinger;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Grant Or Contract) with Acerta;.

Sasha Stanton, MD PhD

has a financial relationship (Professional Services) with Stanford Prebys Burnham;.
has a financial relationship (Professional Services) with Margenza;.
has a financial relationship (Grant Or Contract) with IMV Inc;.

Lynn Symonds

has no relevant financial relationships to disclose at this time.

Rajat Thawani, MD

has no relevant financial relationships to disclose at this time.

Scott Tykodi, MD, PhD

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Exelixis;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Professional Services) with FirstWord;.
has a financial relationship (Grant Or Contract) with AVEO Oncology;.
has a financial relationship (Professional Services) with Targeted Oncology;.

Chetan Vakkalagadda

has a financial relationship (Independent contractor) with Takeda Pharmaceuticals USA;.
has a financial relationship (Grant Or Contract) with EGFR Resisters;.
has a financial relationship (Independent contractor) with MJH LifeSciences;.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Prakash Ambady, MD

has no relevant financial relationships to disclose at this time.

Julie Graff, MD

has no relevant financial relationships to disclose at this time.

Qiuying (Selina) Liu, MD

has no relevant financial relationships to disclose at this time.

Sarah Lowry, DNP, ACNP-BC, AOCNP, ACHPN

has a financial relationship (Other) with Galera therapeutics;.

Gabrielle Meyers

has no relevant financial relationships to disclose at this time.

Joshua Press, MD, MSc

has a financial relationship (Other) with GlaxoSmithKline (GSK);.
has a financial relationship (Other) with AstraZeneca;.

Lauren Shih, MD

has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Stock) with Exact Sciences;.

Available Credit

  • 9.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 9.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 9.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 9.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 9.75 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.